EGFR and non-small cell lung carcinoma: Phase Ib/II studies evaluated the efficacy and safety of gefitinib plus capmatinib or tepotinib after the failure of EGFR‐TKI therapy in patients with EGFR‐mutated, MET‐amplified/overexpressing NSCLC, the results of which showed these combination regimes were a promising treatment, especially for patients with a MET gene copy number ≥6 or high (IHC3+) MET overexpression.207, 208